Glioma Clinical Trials

Find Glioma Clinical Trials Near You

Assessing Brain Metabolism Using 1H MRS With Deuterated Glucose

Status: Recruiting
Location: See location...
Intervention Type: Drug, Procedure
Study Type: Observational
SUMMARY

This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Participants must be \>= 18 years old

‣ Cohort 1: Healthy controls

⁃ Cohort 2: Participants with histological proven glioma who have evidence of evaluable disease (with contrast enhancing lesion or non-enhancing lesion \> 4 cc) based on a prior MR scan.

⁃ Cohort 3: Participants with histologically proven glioma who will be undergoing any treatment.

• Participants must not have any significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the subject's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.

• Participants must not be pregnant or breast-feeding. Persons of childbearing potential are required to obtain a negative serum or urine pregnancy test within 14 days of the scan. Effective contraception (men and women) must be used in subjects of childbearing potentials.

• Participants must sign an informed consent indicating that they are aware of the investigational nature of the study

Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Wendy Ma
Wendy.Ma@ucsfe.du
(415) 514-4418
Time Frame
Start Date: 2022-07-20
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 80
Treatments
Cohort 1: Healthy Controls
Twenty healthy controls for will have 2H-glucose metabolism in measured for development of robust strategy in optimizing acquisition parameters.
Cohort 2: Glioma participants (Single Time point)
Thirty participants with glioma who may or may not have received prior treatment for testing the optimized imaging protocol developed in Cohort 1.
Cohort 3: Glioma participants (Multiple Time points)
Thirty participants who will receive non-investigational treatment for glioma enrolled to test the evaluation for treatment induced metabolic changes at baseline and post- non-investigational treatment.
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco

This content was sourced from clinicaltrials.gov